SK ChemicalsLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

SK ChemicalsLtd şirketinin toplam hissedar öz sermayesi ₩2,731.2B ve toplam borcu ₩1,535.7B olup, bu da borç-öz sermaye oranını 56.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₩4,646.4B ve ₩1,915.3B dir. SK ChemicalsLtd 'in FAVÖK'ü ₩85.2B faiz karşılama oranı 5.2 dur. Şirketin ₩1,681.6B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

56.2%

Borç/özkaynak oranı

₩1.54t

Borç

Faiz karşılama oranı	5.2x
Nakit	₩1.68t
Eşitlik	₩2.73t
Toplam yükümlülükler	₩1.92t
Toplam varlıklar	₩4.65t

Son finansal sağlık güncellemeleri

We Think SK ChemicalsLtd (KRX:285130) Can Stay On Top Of Its Debt

Oct 26

Recent updates

We Think SK ChemicalsLtd (KRX:285130) Can Stay On Top Of Its Debt

Oct 26

SK Chemicals Co.,Ltd's (KRX:285130) Price Is Out Of Tune With Revenues

Aug 12

We Think That There Are More Issues For SK ChemicalsLtd (KRX:285130) Than Just Sluggish Earnings

Mar 22

Imagine Holding SK ChemicalsLtd (KRX:285130) Shares While The Price Zoomed 499% Higher

Mar 02

An Intrinsic Calculation For SK Chemicals Co.,Ltd. (KRX:285130) Suggests It's 21% Undervalued

Feb 08

SK Chemicals Co.,Ltd. (KRX:285130) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Jan 20

What Type Of Shareholders Own The Most Number of SK Chemicals Co.,Ltd. (KRX:285130) Shares?

Dec 30

When Should You Buy SK Chemicals Co.,Ltd. (KRX:285130)?

Dec 09

Did You Miss SK ChemicalsLtd's (KRX:285130) Whopping 729% Share Price Gain?

Nov 19

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: A285130 'nin kısa vadeli varlıkları ( ₩2,419.7B ) kısa vadeli yükümlülüklerini ( ₩1,013.9B ) aşıyor.

Uzun Vadeli Yükümlülükler: A285130 şirketinin kısa vadeli varlıkları ( ₩2,419.7B ) uzun vadeli yükümlülüklerini ( ₩901.3B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: A285130 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: A285130 'nin borç/öz sermaye oranı son 5 yılda 140.8% seviyesinden 56.2% seviyesine düştü.

Borç Kapsamı: A285130 'nin borcu işletme nakit akışı ( 14.5% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: A285130 'in borcuna ilişkin faiz ödemeleri EBIT ( 5.2 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

SK ChemicalsLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think SK ChemicalsLtd (KRX:285130) Can Stay On Top Of Its Debt

Recent updates

We Think SK ChemicalsLtd (KRX:285130) Can Stay On Top Of Its Debt

SK Chemicals Launches ECOTRIA CLARO 300 with Improved Recyclability

SK Chemicals Co.,Ltd(KOSE:A285130) dropped from FTSE All-World Index (USD)

Consensus EPS estimates increase by 1,301%

SK Chemicals Co.,Ltd's (KRX:285130) Price Is Out Of Tune With Revenues

Upcoming dividend of ₩400 per share

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: ₩214 loss per share (vs ₩816 profit in 1Q 2023)

SK chemicals Unveils Blueprint for Circular Recycle™ and Solutions

SK Chemicals, Dongsung Chemical, and Black Yak Collaborate on Commercializing Sustainable Footwear

We Think That There Are More Issues For SK ChemicalsLtd (KRX:285130) Than Just Sluggish Earnings

Full year 2023 earnings released: EPS: ₩2,072 (vs ₩9,910 in FY 2022)

There Is A Reason SK Chemicals Co.,Ltd's (KRX:285130) Price Is Undemanding

Upcoming dividend of ₩1,100 per share at 2.2% yield

Third quarter 2023 earnings released: EPS: ₩2,441 (vs ₩1,815 in 3Q 2022)

Glenwood Private Equity signed a memorandum of understanding to acquire the Pharmaceutical business of SK Chemicals Co.,Ltd (KOSE:A285130).

New minor risk - Profit margin trend

Upcoming dividend of ₩400 per share at 1.5% yield

First quarter 2023 earnings released: EPS: ₩816 (vs ₩1,881 in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to ₩130,000

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Price target increased to ₩333,333

Price target increased to ₩333,333

Upcoming dividend of ₩1,333 per share

Metrica Partners Calls for a Strategic Review at SK Chemicals

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Metrica Partners Sends Letter to SK Chemicals

We Think SK ChemicalsLtd's (KRX:285130) Robust Earnings Are Conservative

Full year 2020 earnings released: EPS ₩621 (vs ₩1,318 loss in FY 2019)

Should You Think About Buying SK Chemicals Co.,Ltd. (KRX:285130) Now?

Investor sentiment deteriorated over the past week

SK Chemicals Co.,Ltd., Annual General Meeting, Mar 31, 2021

Investor sentiment deteriorated over the past week

New 90-day low: ₩347,000

Imagine Holding SK ChemicalsLtd (KRX:285130) Shares While The Price Zoomed 499% Higher

Daejung Chemicals & Metals Co.,Ltd. (KOSDAQ:A120240) acquired 50% in Sk Chemicals Daejung Co,. Ltd from SK Chemicals Co.,Ltd. (KOSE:A285130) for KRW 6 billion.

Price target raised to ₩513,333

An Intrinsic Calculation For SK Chemicals Co.,Ltd. (KRX:285130) Suggests It's 21% Undervalued

New 90-day high: ₩462,500

SK Chemicals Co.,Ltd. (KRX:285130) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Standigm Inc. and K Chemicals Co., Ltd. Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership

What Type Of Shareholders Own The Most Number of SK Chemicals Co.,Ltd. (KRX:285130) Shares?

Upcoming Dividend of ₩450 Per Share

When Should You Buy SK Chemicals Co.,Ltd. (KRX:285130)?

Analysts increase EPS estimates to ₩17,352

Did You Miss SK ChemicalsLtd's (KRX:285130) Whopping 729% Share Price Gain?

Analysts update estimates

New 90-day high: ₩449,500

Kyung-joo Park and other investors acquired 16.03% stake in JSI Co. Ltd. from SK Chemicals Co.,Ltd. (KOSE:A285130) for KRW 0.04 million.

New 90-day high - ₩314,000

Price target raised to ₩183,750

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin